Article citationsMore>>

Crijns, A.P., de Graeff, P., Geerts, D., Ten Hoor, K.A., Hollema, H., van der Sluis, T., Hofstra, R.M., de Bock, G.H., de Jong, S., van der Zee, A.G. and de Vries, E.G. (2007) MEIS and PBX Homeobox Proteins in Ovarian Cancer. European Journal of Cancer, 43, 2495-2505.
http://dx.doi.org/10.1016/j.ejca.2007.08.025

has been cited by the following article:

• TITLE: Meis1 Is Required for c-Met Inhibition to Suppress Cell Proliferation of Skin Squamous Cell Carcinoma Cells

  AUTHORS: Megumi Saito, Kazuhiro Okumura, Yasuhiro Yoshizawa, Haruka Munakata, Eriko Isogai, Yuichi Wakabayashi

  KEYWORDS: Meis1, c-Met, Skin Squamous Cell Carcinoma

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.4 No.7, July 11, 2016

  ABSTRACT: Previous studies have shown that Meis1 plays an important role in the pathogenesis of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Meis1 belongs to the TALE family, the members of which are used as biomarkers for AML. Meis1 has been shown to play a functional role in epithelial tissues, such as skin. However, its functions in skin carcinogenesis remain poorly understood. On the other hand, the c-Met inhibitor SU11274 has been identified through drug screening with HOXA9/Meis1-induced AML cell lines. SU11274 altered cell proliferation and the cell cycle status in human AML cell lines. Thus, we hypothesized that the effects of SU11274 are dependent on Meis1 and that its knockdown may diminish the effects of SU11274 not only in AML cell lines, but also in skin cancer cell lines. In order to test our hypothesis, we established Meis1 knockdown cell lines using two skin squamous cell carcinoma cell lines (B9 and D3) and treated these cell lines with SU11274. The results obtained showed that SU11274 suppressed cell proliferation by modulating cell cycle progression in the presence of Meis1, but not in its absence. Furthermore, an expression analysis showed that SU11274 activated the transcription of Meis1, which led to the transcription of Hif1α and Cdkn2a (p16Ink4a and p19Arf). These results suggest that Meis1 is required for the c-Met inhibitor SU11274 to suppress the proliferation of the skin squamous cell carcinoma cell lines.